Contact our team of experts to place an inquiry.
Chris J. Bai, Ph.D.
Chief Financial Officer of the Ambio Holdings, the parent of Ambio and AmbioPharm. He is responsible for financial reporting, cash management, banking relations, investor relations, and government liaison. Mr. Kiel has served as CFO in five previous and CEO in two prior companies and has consulted to more than 150 businesses. He was a Partner with Deloitte Consulting (a Big Four accounting firm). Mr. Kiel holds an MBA from the Ohio State University and was awarded a CPA and Series 7 license.
As Chief Operating Officer, he is responsible for overall operations for the company in US and China. Since 1993, he has held numerous roles in the development, manufacturing, and business management of both clinical development and commercialization of peptide based therapeutics. He has been involved in the successful commercialization of multiple peptide products, from small gram scale to kilogram scale. Prior to Ambiopharm, he worked at Mallinckrodt Pharmaceuticals, which in addition to the peptide division, his experience also included the management of other small molecule commercial generic products and excipients. He also holds an MBA from Maryville University.
Executive Vice President of Business Development and cGMP Sales. He is responsible for contract manufacturing of synthetic peptides and small molecules to be manufactured under cGMP as generic peptide APIs and API’s for human clinical trials. Since 1995, he has developed and maintained worldwide business relationships with scientists in academia, government and private industry. He has managed over 300 projects involving cGMP grade peptides in scales from grams to kilograms at manufacturing facilities at Peninsula Laboratories, Bachem, American Peptide Company and AmbioPharm.
Senior Vice President of Business Development and co-founder, is responsible for the business development of the company’s generic API business unit. Dr. Geiger has 20+ years of experience in Business Development, Generic API development, and Quality Systems management. He currently serves on the DCAT advisory board and the International GMP Conference (Athens, GA) board. Prior to AmbioPharm, Dr. Geiger was employed by American Peptide Company and UCB Bioproducts in the area of Business Development and Quality Control.
He is responsible for sales and technical advice for the contract manufacturing of synthetic peptides, pegylated peptides and peptide protein conjugates to be manufactured as either non GMP or cGMP including generic peptide APIs and API’s for human clinical trials. Since 1988, he has developed and maintained worldwide collaborations and business relationships with scientists in academia, government and private industry. He has a publication record of more than 110 peer reviewed papers on the synthesis and development of complex peptides for the treatment of human disease. With a career centered around research and development of peptides, he has participated in numerous programs which evolved into the requirement of cGMP grade peptides at scales from grams to kilograms. Dr Pennington was part of the management team with a 20+ year career at Bachem Bioscience followed by 7+ years as President and CEO at Peptides International.
President, Ambio, Inc., is globally responsible for the company’s operations including North America, Europe, Japan, and China. Dr. Singh has more than 16 years of broad range experience in Analytical R&D, Formulation, Drug Product Development, Regulatory, and Quality Control. He has been a key player in taking multiple complex generic projects from R&D to commercial stage. He also plays key role in strategic partnerships with various large generic pharma companies and CDO/CMO/CRO’s across the world.
Vice President of Manufacturing and Process Development is responsible for manufacturing and process development in the Company’s China facilities. He has more than 15 years’ experience in peptide process development, cGMP manufacturing and process validation.